C3N-00547
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 60.78576318
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.350
- KRAS_SIGNALING_DN+0.240
- ESTROGEN_RESPONSE_LATE+0.210
- ESTROGEN_RESPONSE_EARLY+0.200
- PANCREAS_BETA_CELLS+0.200
- NOTCH_SIGNALING+0.190
- ANGIOGENESIS+0.170
- MYOGENESIS+0.170
- TGF_BETA_SIGNALING+0.150
- INTERFERON_GAMMA_RESPONSE+0.110
Top 10 suppressed
- MYC_TARGETS_V1-0.500
- PROTEIN_SECRETION-0.380
- ALLOGRAFT_REJECTION-0.360
- DNA_REPAIR-0.330
- E2F_TARGETS-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- MTORC1_SIGNALING-0.260
- KRAS_SIGNALING_UP-0.250
- IL6_JAK_STAT3_SIGNALING-0.220
- ADIPOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613702 | — | C | 0.771 |
| 2 | BS_NNPEC7W1 | high-grade glioma | — | 0.767 |
| 3 | SRR25617906 | — | B | 0.758 |
| 4 | ERR4976607 | — | B | 0.746 |
| 5 | TCGA-55-8507-01A-11R-2403-07 | — | cohortA3 | 0.733 |
| 6 | ERR4976623 | — | B | 0.729 |
| 7 | TCGA-49-AARN-01A-21R-A41B-07 | — | cohortA1 | 0.728 |
| 8 | SRR1378155 | GTEX | — | 0.720 |
| 9 | MDT-AP-0760 | Med | Medulloblastoma | 0.715 |
| 10 | SRR1489779 | GTEX | — | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.090 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |